1. Home
  2. OMER vs SNDA Comparison

OMER vs SNDA Comparison

Compare OMER & SNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • SNDA
  • Stock Information
  • Founded
  • OMER 1994
  • SNDA 1990
  • Country
  • OMER United States
  • SNDA United States
  • Employees
  • OMER N/A
  • SNDA N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • SNDA Hospital/Nursing Management
  • Sector
  • OMER Health Care
  • SNDA Health Care
  • Exchange
  • OMER Nasdaq
  • SNDA Nasdaq
  • Market Cap
  • OMER 532.0M
  • SNDA 462.3M
  • IPO Year
  • OMER 2009
  • SNDA 1997
  • Fundamental
  • Price
  • OMER $9.18
  • SNDA $25.11
  • Analyst Decision
  • OMER Buy
  • SNDA Hold
  • Analyst Count
  • OMER 4
  • SNDA 1
  • Target Price
  • OMER $22.50
  • SNDA $25.00
  • AVG Volume (30 Days)
  • OMER 422.2K
  • SNDA 27.0K
  • Earning Date
  • OMER 03-31-2025
  • SNDA 03-26-2025
  • Dividend Yield
  • OMER N/A
  • SNDA N/A
  • EPS Growth
  • OMER N/A
  • SNDA N/A
  • EPS
  • OMER N/A
  • SNDA N/A
  • Revenue
  • OMER N/A
  • SNDA $253,196,000.00
  • Revenue This Year
  • OMER N/A
  • SNDA $14.30
  • Revenue Next Year
  • OMER N/A
  • SNDA $9.72
  • P/E Ratio
  • OMER N/A
  • SNDA N/A
  • Revenue Growth
  • OMER N/A
  • SNDA 10.95
  • 52 Week Low
  • OMER $2.61
  • SNDA $10.99
  • 52 Week High
  • OMER $13.60
  • SNDA $34.26
  • Technical
  • Relative Strength Index (RSI)
  • OMER 51.19
  • SNDA 56.72
  • Support Level
  • OMER $9.06
  • SNDA $24.99
  • Resistance Level
  • OMER $9.43
  • SNDA $26.46
  • Average True Range (ATR)
  • OMER 0.52
  • SNDA 0.93
  • MACD
  • OMER 0.08
  • SNDA 0.10
  • Stochastic Oscillator
  • OMER 52.25
  • SNDA 67.94

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About SNDA Sonida Senior Living Inc.

Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.

Share on Social Networks: